Impact of Disease‐Modifying Therapies on Brain and Spinal Cord Atrophy in Multiple Sclerosis
- 1 July 2004
- journal article
- Published by Wiley in Journal of Neuroimaging
- Vol. 14 (s3), 54S-64S
- https://doi.org/10.1111/j.1552-6569.2004.tb00279.x
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategiesExpert Opinion on Investigational Drugs, 2003
- Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2002
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlatesMultiple Sclerosis Journal, 2001
- Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patientsMultiple Sclerosis Journal, 2000
- Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1aMultiple Sclerosis Journal, 2000
- Progressive cerebral atrophy in multiple sclerosis A serial MRI studyBrain, 1996
- Spinal cord atrophy and disability in multiple sclerosisBrain, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995